Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK plus NSCLC

被引：3
|
作者：
Mazieres, J. [1 ]
Novello, S. [2 ]
De Castro, J. [3 ]
Migliorino, M. R. [4 ]
Helland, A. [5 ,6 ]
Dziadziuszko, R. [7 ]
Griesinger, F. [8 ]
Wolf, J. [9 ]
Zeaiter, A. [10 ]
Cardona, A. [10 ]
Balas, B. [10 ]
Karagiannis, T. [11 ,12 ]
Chlistalla, M. [10 ]
Smoljanovic, V. [10 ]
Oh, I. [12 ]
机构：
[1] Toulouse Univ Hosp, Toulouse, France
[2] Univ Turin, Dept Oncol, Turin, Italy
[3] Univ Hosp La Paz, Dept Med Oncol, Madrid, Spain
[4] San Camillo Forlanini Hosp, Dept Lung Dis, Rome, Italy
[5] Radiumhosp, Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway
[6] Radiumhosp, Oslo Univ Hosp, Inst Canc Res, Dept Oncol, Oslo, Norway
[7] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland
[8] Carl von Ossietzky Univ Oldenburg, Pius Hosp, Oncol, Oldenburg, Germany
[9] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany
[10] F Hoffmann La Roche Ltd, Basel, Switzerland
[11] Genentech Inc, San Francisco, CA 94080 USA
[12] Chonnam Natl Univ, Hwasun Hosp, Jeonnam, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Alectinib; chemotherapy; NSCLC;
D O I：
10.1016/j.jtho.2017.09.667
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-013
引用
收藏
页码：S1897 / S1897
页数：1
相关论文
共 50 条
  • [1] CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK plus NSCLC
    de Castro, J.
    Novello, S.
    Mazieres, J.
    Oh, I-J.
    Migliorino, M. R.
    Helland, A.
    Dziadziuszko, R.
    Griesinger, F.
    de Marinis, F.
    Zeaiter, A.
    Cardona, A.
    Balas, B.
    Johannsdottir, H.
    Chlistalla, M.
    Smoljanovic, V.
    Wolf, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] PHASE III STUDY OF CRIZOTINIB VS. CHEMOTHERAPY IN ADVANCED ALK plus NSCLC: PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE
    Nokihara, H.
    Hirsh, V.
    Blackhall, F.
    Kim, D. -W.
    Besse, B.
    Han, J. -Y.
    Wilner, K.
    Reisman, A.
    Iyer, S.
    Shaw, A.
    ANNALS OF ONCOLOGY, 2013, 24
  • [3] Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK plus non-small-cell lung cancer (NSCLC)
    Novello, S.
    Mazieres, J.
    Oh, I-J.
    de Castro, J.
    Migliorino, M. R.
    Helland, A.
    Dziadziuszko, R.
    Griesinger, F.
    Kotb, A.
    Zeiter, A.
    Cardona, A.
    Balas, B.
    Johannsdottir, H.
    Das-Gupta, A.
    Wolf, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK plus non-small cell lung cancer (NSCLC)
    Wolf, J.
    Oh, I-J.
    Mazieres, J.
    de Castro, J.
    Revil, C.
    Kotb, A.
    Johansdottir, H.
    Zeaiter, A.
    Novello, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Phase 3 ALUR Study of Alectinib in Pretreated ALK plus NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses
    Wolf, J.
    Helland, A.
    Oh, I.
    Migliorino, M. R.
    Dziadziuszko, R.
    De Castro Carpeno, J.
    Mazieres, J.
    Griesinger, F.
    Chlistalla, M.
    Cardona, A.
    Ruf, T.
    Trunzer, K.
    Smoljanovic, V.
    Novello, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S210 - S210
  • [6] Pooled Analysis of CNS Response to Alectinib in Two Studies of Pre-Treated ALK plus NSCLC
    Gadgeel, Shirish
    Shaw, A.
    Govindan, Ramaswamy
    Socinski, Mark A.
    Camidge, Ross
    De Petris, Luigi
    Kim, Dong-Wan
    Chiappori, Alberto
    Moro-Sibilot, Denis
    Duruisseaux, Michael
    Crino, Lucio
    De Pas, Tommaso
    Dansin, Eric
    Tessmer, Antje
    Yang, James Chih-Hsin
    Ji-Youn, Han
    Bordogna, Walter
    Golding, Sophie
    Zeaiter, Ali
    Ou, Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S238 - S238
  • [7] Patient-reported outcomes in a phase II study of alectinib
    Ohe, Yuichiro
    ESMO OPEN, 2018, 3 (05)
  • [8] Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK plus NSCLC Treated with Crizotinib vs Chemotherapy
    Lu, You
    Zhou, Jianying
    Chung, Chin-Hee
    Masters, Elizabeth
    Wilner, Keith
    Selaru, Paulina
    Tang, Yiyun
    Wu, Yi Long
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1167 - S1167
  • [9] Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC)
    Perol, M.
    Peters, S.
    Pavlakis, N.
    Levchenko, E.
    Platania, M.
    Oliveira, J.
    Novello, S.
    Karagiannis, T.
    Zeaiter, A.
    Dziadziuszko, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S80 - S81
  • [10] Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK plus NSCLC
    Mazieres, J.
    Iadeluca, L.
    Shaw, A.
    Solomon, B.
    Bauer, T.
    De Marinis, F.
    Felip, E.
    Goto, Y.
    Kim, D.
    Mok, T.
    Reisman, A.
    Thurm, H.
    Polli, A.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S175 - S176
12345